Juluca
Latest Results Show DTG-RPV Combo Provides Long-Term HIV Suppression
The three-year results from the SWORD 1 and 2 trials demonstrated that 84% of participants who switched from their ...
MAY 3, 2019
Dolutegravir Maintains Virologic Suppression in Multiple Trials
Dolutegravir-based regimens provide long-term suppression in HIV patients, according to presentations at the 22nd ...
JULY 26, 2018
FDA Warns of Neural Tube Birth Defects With Dolutegravir
The FDA issued an alert about serious cases of neural tube birth defects involving the brain, spine and spinal cord ...
MAY 18, 2018
Load more